Share on StockTwits

Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Tuesday.

Agenus (NASDAQ:AGEN) traded up 12.42% on Tuesday, hitting $3.62. The stock had a trading volume of 7,375,944 shares. Agenus has a 1-year low of $2.27 and a 1-year high of $5.27. The stock has a 50-day moving average of $3.09 and a 200-day moving average of $3.18. The company’s market cap is $225.3 million.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, May 8th. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.12. The company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.55 million. On average, analysts predict that Agenus will post $-0.54 earnings per share for the current fiscal year.

A number of other firms have also recently commented on AGEN. Analysts at Maxim Group cut their price target on shares of Agenus from $17.00 to $11.00 in a research note on Thursday, May 8th. They now have a “buy” rating on the stock. Analysts at Zacks upgraded shares of Agenus from a “neutral” rating to an “outperform” rating in a research note on Monday, April 21st. They now have a $3.00 price target on the stock.

Agenus Inc, including its subsidiaries, (NASDAQ:AGEN) is a biotechnology company focused on the development and commercialization of technologies to treat cancers and infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.